Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities (2017 - 2026)

Kiniksa Pharmaceuticals International's Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$31.9 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 38.08% year-over-year to -$31.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$169.4 million (down 329.94% YoY) and the FY2025 annual result came in at -$189.0 million, down 601.68% from the prior year.
• Cash from Investing Activities was -$31.9 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from -$70.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $65.3 million in Q4 2024 and bottomed at -$70.8 million in Q4 2025.
• A 5-year average of -$13.0 million and a median of -$14.9 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities jumped 538.38% — and 2025, when it plunged 888.58%.
• Kiniksa Pharmaceuticals International's Cash from Investing Activities stood at -$42.7 million in 2022, then soared by 65.09% to -$14.9 million in 2023, then soared by 538.38% to $65.3 million in 2024, then plunged by 208.46% to -$70.8 million in 2025, then soared by 54.93% to -$31.9 million in 2026.
• Business Quant data shows KNSA's Cash from Investing Activities at -$31.9 million in Q1 2026, -$70.8 million in Q4 2025, and -$62.8 million in Q3 2025.